Legal Claims for People Who Have Used Xarelto
Goldberg & Osborne attorneys are investigating potential claims for users of the prescription blood thinner Xarelto (rivaroxaban) who may have sustained serious bleeding episodes, strokes, and death. If you or a loved one has suffered a serious bleeding event, stroke, or died after using Xarelto, call Goldberg & Osborne at 1‑800‑THE‑EAGLE (1‑800‑843‑3245) or follow the link below to send us an email requesting a free case evaluation to determine whether Goldberg & Osborne may be able to assist you. There are no fees or costs until your case is settled or won.
What is Xarelto?
Xarelto is an oral prescription blood thinner, also known as an anticoagulant, developed by Bayer and distributed in the United States by Janssen Pharmaceuticals, a unit of Johnson & Johnson. It was approved by the Food and Drug Administration (the FDA) in July 2011. It is in a class of new anticoagulants that stop the blood from clotting in novel ways. According to Janssen, Xarelto inhibits free Factor Xa (FXa) in the blood which in turn reduces certain blood clots.
As the name suggests, the purpose of anticoagulants is to treat or reduce coagulation, the clotting of blood. Anticoagulation therapy is often necessary for people with certain medical conditions. Xarelto has been approved by the FDA to reduce the risk of stroke in patients with atrial fibrillation, to reduce the risk of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) from occurring after hip or knee replacement surgery, and to treat and reduce the risk of recurrent DVTs and PEs.
Why is Xarelto Dangerous?
While it is important for patients with certain medical conditions to have the clotting tendency of their blood reduced, if the clotting tendency is reduced too much and a patient suffers a bleeding event, the blood will not clot to stop the bleeding. Therefore, a delicate balance between too much and too little of the anticoagulant therapy must be achieved when someone is prescribed a blood thinner.
To achieve this balance, patients prescribed older blood thinners, such as Coumadin (warfarin), are carefully monitored to ensure that the blood’s clotting tendency is decreased, but not reduced too much. When a patient is first prescribed Coumadin, the blood may be tested every day until the right balance is found. Thereafter, additional blood tests are usually performed every one to four weeks. All this testing can be very disruptive to a patient’s normal daily activities, but is necessary to ensure that the blood’s clotting tendency is within an appropriate range.
Xarelto is marketed as being more convenient than the older blood thinners in that blood monitoring is not required. According to Janssen, the dose prescribed does not need to be modified in light of a patient’s age, weight, or gender. Dose is only dependent upon the medical condition for which it is prescribed. It is questioned whether this lack of customization to each patient and of monitoring throughout Xarelto use is sufficient to reach the delicate balance necessary to reduce blood clots while still allowing the blood to clot before bleeding damages vital organs.
What makes Xarelto even more dangerous is that there is no antidote for it. When a serious bleeding event occurs in a patient taking Coumadin (warfarin), the anticoagulant effect of the drug can be stopped with the administration of Vitamin K. Xarelto is much more dangerous than Coumadin (warfarin), because vitamin K will not stop uncontrolled bleeding when it occurs. None of the traditional methods used to stop bleeding in patients using Coumadin (warfarin) are proven to stop bleeding in patients using Xarelto. Xarelto patients will continue to bleed until enough of the active ingredient in Xarelto is flushed from the body through the body’s normal systems to allow the blood to clot at the site of the bleed.
Xarelto Lawsuit History
Dating back to 2014, numerous lawsuits have been filed against Bayer and Janssen Pharmaceuticals for serious bleeding episodes as a result of taking Xarelto. Despite these lawsuits and the new complaints being filed regularly, neither company has issued a warning to current or prospective patients about the uncontrollable bleeding dangers of taking the drug. Sales of Xarelto continue to rise and are expected to reach $3.68 billion annually by 2018.
Experienced Goldberg & Osborne Attorneys Can Investigate Your Claim
If you or a loved one has suffered a serious bleeding episode, stroke or death as a result of using Xarelto, you may be entitled to compensation from the manufacturer and distributor of the drug. Call Goldberg & Osborne toll-free at 1‑800‑THE‑EAGLE (1‑800‑843‑3245) for a free consultation, or submit a short online case inquiry here so that Goldberg & Osborne can contact you. All states have time limits in which claims must be filed, or they will be forever barred; therefore, it is crucial that you contact Goldberg & Osborne immediately.
Goldberg & Osborne has been helping people injured by the negligence of others, including multinational pharmaceutical and medical device manufacturers, since 1989. Goldberg & Osborne attorneys practice law only in Arizona but associate with attorneys throughout the United States.